• Idorsia submits investigational insomnia treatment daridorexant to the EMA pharmatimes
    March 03, 2021
    Swiss biotech company Idorsia has submitted a marketing authorisation application to the European Medicines Agency (EMA) for its investigational insomnia treatment daridorexant.
  • Idorsia Partners with Syneos Health contractpharma
    September 01, 2020
    ​Idorsia Ltd and Syneos Health have formed a commercial relationship for the U.S. commercialization of Idorsia’s daridorexant, a new dual orexin receptor antagonist being investigated for the treatment of insomnia.
PharmaSources Customer Service